| Literature DB >> 33238112 |
Anna Pensalfini1, Seonil Kim2, Shivakumar Subbanna3, Cynthia Bleiwas4, Chris N Goulbourne5, Philip H Stavrides5, Ying Jiang1, Ju-Hyun Lee1, Sandipkumar Darji5, Monika Pawlik5, Chunfeng Huo5, James Peddy5, Martin J Berg5, John F Smiley4, Balapal S Basavarajappa6, Ralph A Nixon7.
Abstract
Neuronal endosomal dysfunction, the earliest known pathobiology specific to Alzheimer's disease (AD), is mediated by the aberrant activation of Rab5 triggered by APP-β secretase cleaved C-terminal fragment (APP-βCTF). To distinguish pathophysiological consequences specific to overactivated Rab5 itself, we activate Rab5 independently from APP-βCTF in the PA-Rab5 mouse model. We report that Rab5 overactivation alone recapitulates diverse prodromal and degenerative features of AD. Modest neuron-specific transgenic Rab5 expression inducing hyperactivation of Rab5 comparable to that in AD brain reproduces AD-related Rab5-endosomal enlargement and mistrafficking, hippocampal synaptic plasticity deficits via accelerated AMPAR endocytosis and dendritic spine loss, and tau hyperphosphorylation via activated glycogen synthase kinase-3β. Importantly, Rab5-mediated endosomal dysfunction induces progressive cholinergic neurodegeneration and impairs hippocampal-dependent memory. Aberrant neuronal Rab5-endosome signaling, therefore, drives a pathogenic cascade distinct from β-amyloid-related neurotoxicity, which includes prodromal and neurodegenerative features of AD, and suggests Rab5 overactivation as a potential therapeutic target.Entities:
Keywords: Alzheimer’s disease; Rab5 hyperactivation; aberrant endosomal signaling; amyloid precursor protein; cholinergic neurodegeneration; endosomal dysfunction; memory impairment; spine loss; synaptic deficits; tau
Mesh:
Substances:
Year: 2020 PMID: 33238112 PMCID: PMC7714675 DOI: 10.1016/j.celrep.2020.108420
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423